Stock Detail
NOVO NORDISK A/S
Sector: Drug Manufacturers Other
Latest Quote @ Sat May 5 14:58:38 (15 min delayed)
| $170.00 |
$175.50 |
$171.99 |
+0.00 |
0.00% |
|
Last Day's Data
| $171.99 |
$172.43 |
$0.00 |
0.00% |
2.26 |
$171.99 |
| $170.95 |
$170.66 |
213,068.00 |
93.24B |
232,986.00 |
24.72 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 173.46 |
172.72 |
171.69 |
170.95 |
169.92 |
Stock Profile
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products and services. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment comprises insulin franchise, including insulin analogues, human insulin and insulin-related sales, and oral antidiabetic drugs. The Biopharmaceutical segment includes therapy areas, such as hemostasis management, growth hormone therapy and hormone replacement therapy, and other products. Novo Nordisk distributes its products primarily through distributors and independent agents. The company markets its products primarily in North America, Japan, and Europe. Novo Nordisk has a collaboration agreement with Aurigene Discoveries Technologies, which encompasses a joint discovery effort by both the companies on a target covering the discovery and preclinical development of lead series at Aurigene. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
